RESUMO
BACKGROUND: The EphB2 gene was recently implicated as a prostate cancer (PC) tumour suppressor gene, with somatic inactivating mutations occurring in approximately 10% of sporadic tumours. We evaluated the contribution of EphB2 to inherited PC susceptibility in African Americans (AA) by screening the gene for germline polymorphisms. METHODS: Direct sequencing of the coding region of EphB2 was performed on 72 probands from the African American Hereditary Prostate Cancer Study (AAHPC). A case-control association analysis was then carried out using the AAHPC probands and an additional 183 cases of sporadic PC compared with 329 healthy AA male controls. In addition, we performed an ancestry adjusted association study where we adjusted for individual ancestry among all subjects, in order to rule out a spurious association due to population stratification. RESULTS: Ten coding sequence variants were identified, including the K1019X (3055A-->T) nonsense mutation which was present in 15.3% of the AAHPC probands but only 1.7% of 231 European American (EA) control samples. We observed that the 3055A-->T mutation significantly increased risk for prostate cancer over twofold (Fisher's two sided test, p = 0.003). The T allele was significantly more common among AAHPC probands (15.3%) than among healthy AA male controls (5.2%) (odds ratio 3.31; 95% confidence interval 1.5 to 7.4; p = 0.008). The ancestry adjusted analyses confirmed the association. CONCLUSIONS: Our data show that the K1019X mutation in the EphB2 gene differs in frequency between AA and EA, is associated with increased risk for PC in AA men with a positive family history, and may be an important genetic risk factor for prostate cancer in AA.
Assuntos
Negro ou Afro-Americano/genética , Códon sem Sentido , Predisposição Genética para Doença , Neoplasias da Próstata/etnologia , Neoplasias da Próstata/genética , Receptor EphB2/genética , Adulto , Idoso , Alelos , Testes Genéticos , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo Genético , Neoplasias da Próstata/diagnóstico , Fatores de Risco , Estados UnidosRESUMO
The 999del5 mutation is the single, strong BRCA2 founder mutation in Iceland and the most common BRCA1/2 founder mutation in Finland. To evaluate the origin and time since spreading of the 999del5 mutation in Iceland and in Finland, we constructed haplotypes with polymorphic markers within and flanking the BRCA2 gene in a set of 18 Icelandic and 10 Finnish 999del5 breast cancer families. All Icelandic families analysed shared a common core haplotype of about 1.7 cM. The common ancestors for the Icelandic families studied were estimated to trace back to 340-1000 years, not excluding the possibility that the mutation was brought to Iceland during the settlement of the country. Analysis of the Finnish families revealed two distinct haplotypes. A rare one, found in three families in the old settlement region in southwestern Finland, shared a four-marker (0.5 cM) core haplotype with the Icelandic 999del5 haplotype. A distinct approximately 6 cM haplotype was shared by seven 999del5 Finnish families estimated to have a common ancestry 140-300 years ago. These families cluster in two geographical regions in Finland, in the very same area as those with the rare haplotype and also in the most eastern, late settlement region of Finland. The results may indicate a common ancient origin for the 999del5 mutation in Iceland and in Finland, but distinct mutational events cannot be ruled out. The surprising finding of the same mutation in two completely different haplotypes in a sparsely populated area in Finland may suggest gene conversion.
Assuntos
Neoplasias da Mama/genética , Genes BRCA2 , Haplótipos/genética , Deleção de Sequência/genética , Etnicidade/genética , Feminino , Finlândia , Marcadores Genéticos , Geografia , Humanos , Islândia , Neoplasias Ovarianas/genética , Filogenia , Fatores de TempoRESUMO
In the Finnish breast and ovarian cancer families six BRCA1 and five BRCA2 mutations have been found recurrently. Some of these recurrent mutations have also been seen elsewhere in the world, while others are exclusively of Finnish origin. A haplotype analysis of 26 Finnish families carrying a BRCA1 mutation and 20 families with a BRCA2 mutation indicated that the carriers of each recurrent mutation have common ancestors. The common ancestors were estimated to trace back to 7-36 generations (150-800 years). The time estimates and the geographical clustering of these founder mutations in Finland are in concordance with the population history of this country. Analysis of the cancer phenotypes showed differential ovarian cancer expression in families carrying mutations in the 5' and 3' ends of the BRCA1 gene, and earlier age of ovarian cancer onset in families with BRCA1 mutations compared with families with BRCA2 mutations. The identification of prominent and regional BRCA1 and BRCA2 founder mutations in Finland will have significant impact on diagnostics in Finnish breast and ovarian cancer families. An isolated population with known history and multiple local founder effects in multigenic disease may offer distinct advantages also for mapping novel predisposing genes.
Assuntos
Neoplasias da Mama/genética , Efeito Fundador , Genes BRCA1/genética , Mutação/genética , Proteínas de Neoplasias/genética , Neoplasias Ovarianas/genética , Fatores de Transcrição/genética , Adulto , Idoso , Proteína BRCA2 , Neoplasias da Mama/patologia , Família , Feminino , Finlândia/epidemiologia , Genótipo , Haplótipos , Humanos , Pessoa de Meia-Idade , Proteínas de Neoplasias/metabolismo , Neoplasias Ovarianas/patologia , Fenótipo , Fatores de Tempo , Fatores de Transcrição/metabolismoRESUMO
Since the identification of the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes, mutation analyses have been carried out in different populations. Here we screened 15 Turkish breast and breast-ovarian cancer families for mutations in both genes by conformation-sensitive gel electrophoresis (CSGE) and the protein truncation test (PTT), followed by DNA sequencing. Three families included a male breast cancer case, one without family history. Three germline mutations were identified, two in BRCA1 and one in BRCA2. The two BRCA1 mutations, 5382insC and 5622C-->T, were found in breast-ovarian cancer families. The BRCA2 3414delTCAG is a novel mutation detected in a site-specific breast cancer family that included 1 case of male breast cancer. These first results of Turkish families show that the frequency of germline BRCA1 or BRCA2 mutations appears to be high in families with at least 3 breast and/or ovarian cancer cases.
Assuntos
Neoplasias da Mama Masculina/genética , Genes BRCA1/genética , Mutação em Linhagem Germinativa/genética , Proteínas de Neoplasias/genética , Fatores de Transcrição/genética , Idade de Início , Proteína BRCA2 , Feminino , Predisposição Genética para Doença , Humanos , Masculino , Neoplasias Ovarianas/genética , Linhagem , Projetos Piloto , Turquia/epidemiologiaRESUMO
Mutations in BRCA1 and BRCA2 account for a large portion of the inherited predisposition to breast and ovarian cancer. It was recently discovered that mutations in these two genes are less common in the Finnish population than expected. Because the genetic background of breast cancer, in particular, is largely obscure, it became necessary to search for mutations in other susceptibility genes. Because seven of our BRCA1 and BRCA2 mutation-negative families fulfilled the criteria of either Li-Fraumeni syndrome (LFS) or Li-Fraumeni-like syndrome (LFL), we decided to screen them for germ-line TP53 mutations in exons 5-8 using a dual-temperature single-strand conformation polymorphism assay (SSCP). Two missense mutations (Asn235Ser and Tyr220Cys) were identified. The clinical significance of these findings was evaluated by comparison to previously reported germ-line TP53 mutation data, and by using the tumor loss of heterozygosity (LOH) analysis. In addition, an immunohistochemical analysis of tumor specimens from mutation-positive individuals was performed. Our results suggest that the observed missense mutations confer susceptibility to cancer, and that germ-line TP53 mutations would therefore explain an additional fraction of hereditary breast cancer in Finland.
Assuntos
Genes BRCA1 , Genes p53 , Mutação em Linhagem Germinativa , Síndrome de Li-Fraumeni/genética , Proteínas de Neoplasias/genética , Neoplasias/genética , Fatores de Transcrição/genética , Proteína BRCA2 , Feminino , Finlândia , Humanos , Masculino , Neoplasias/etnologia , Linhagem , Polimorfismo Conformacional de Fita SimplesRESUMO
In the Finnish population, identified mutations in BRCA1 and BRCA2 account for a less than expected proportion of hereditary breast and ovarian cancer. All previous studies performed in our country have concentrated on finding germ-line mutations in the coding and splice-site regions of these two genes. Therefore, we wanted to use a different methodological approach and search for large genomic rearrangements, to exclude the possibility of biased BRCA1 and BRCA2 mutation spectra due to known limitations of the previously used PCR-based detection methods. Our results support earlier notions that other genes than BRCA1 and BRCA2 will explain a majority of the still unexplained cases of hereditary susceptibility to breast and ovarian cancer.
Assuntos
Proteína BRCA1/genética , Neoplasias da Mama/genética , Testes Genéticos , Proteínas de Neoplasias/genética , Neoplasias Ovarianas/genética , Deleção de Sequência , Fatores de Transcrição/genética , Proteína BRCA2 , Southern Blotting , Neoplasias da Mama/epidemiologia , Família , Feminino , Finlândia/epidemiologia , Predisposição Genética para Doença , Humanos , Neoplasias Ovarianas/epidemiologiaRESUMO
Tumor specimens from 78 epithelial ovarian cancer patients were examined for loss of heterozygosity (LOH) at 11 microsatellite markers at chromosomes 3p14.2, 6q27, 8p12, 11p15.5, 11q23.1-q24, 16q24.3, and 17p13.1, to evaluate the involvement, possible clustering, and prognostic significance of these lesions in the progression of the disease. The LOH analysis was performed on polymerase chain reaction (PCR)-amplified DNA from sections of paraffin-embedded tumor and normal tissue pairs. In addition to primary tumors, specimens of metastatic tissues were studied from 19 patients. In the combined results from primary and metastatic tumors, LOH frequencies varied between 31% (6q27) and 69% (17p13.1). Only LOH at chromosomal regions 3p14.2 (D3S1300), 11p15.5 (D11S1318), 11q23.3-q24 (D11S1340 and D11S912), 16q24.3 (D16S476 and D16S3028), and 17p13.1 (D17S938) was associated with an adverse disease course. Our results indicate that LOH at 17p13.1 occurs independently from the other chromosomal sites studied, and is an early event in ovarian tumorigenesis. The LOH at 16q24.3, 11q23.3/q24, and 11p15.5 seems to occur later. The LOH at 11p15.5 and 11q23.3 was associated with reduced cancer-specific survival time; therefore, the studied markers could be located close to genes with influence on patient survival. Of the studied chromosomal regions, the most important tumor suppressor genes involved in the evolution of ovarian cancer appear to be located on chromosomes 11, 16, and 17. The genetic heterogeneity observed in primary and metastatic specimens demonstrates that there are multiple pathways involved in the progression of ovarian cancer.
Assuntos
Cromossomos Humanos , Perda de Heterozigosidade , Neoplasias Ovarianas/genética , Deleção Cromossômica , Feminino , Humanos , Neoplasias Ovarianas/patologiaAssuntos
Neoplasias da Mama/genética , Testes Genéticos , Mutação em Linhagem Germinativa/genética , Proteínas Serina-Treonina Quinases/genética , Adulto , Proteínas Mutadas de Ataxia Telangiectasia , Proteínas de Ciclo Celular , Pré-Escolar , Análise Mutacional de DNA , Proteínas de Ligação a DNA , Éxons/genética , Feminino , Finlândia , Predisposição Genética para Doença/genética , Variação Genética/genética , Humanos , Masculino , Linhagem , Polimorfismo Genético/genética , Proteínas Supressoras de TumorRESUMO
Aminopeptidase activities were studied biochemically from the supernatants of the homogenates prepared from the normal and post extraction palatal mucosa of the rat. The determinations were carried out at 0.5, 1, 2, 4, 8 and 16 hours and 1, 2, 3, 5 and 7 days following extraction using N-L-aminoacyl-2-naphthylamines of arginine, glycine, leucine, proline and valine as the substrates. In addition, in the second part of the study the hydrolysis of N-L-aminoacyl-2-naphthylamines of alanine, histidine, isoleucine, lysine, phenylalanine, serine, threonine, tyrosine and valine was tested at 1, 3 and 5 days following extraction. The effect of chloride ions (0.2 M NaCl) on the hydrolysis of arginine and lysine derivatives was also tested. The specific activities of aminopeptidases obtained from the extraction-wound side were compared to those of the control side at each time interval. Tooth extraction caused a considerable reduction in the specific activities of aminopeptidases in the surrounding palatal mucosa immediately after extraction (at 0.5 hr.). The specific activities in the wound tissue remained generally below the control levels for 24 hours and reached their maximum within 5 days following extractions. The highest relative increase was obtained with N-L-valyl-2-naphthylamine. Arginine aminopeptidase was activated by chloride ions on an average 20 per cent more in the wound tissue than the control. This effect can be considered suggestive of the activation of aminopeptidase B in the post extraction palatal mucosa.
Assuntos
Aminopeptidases/metabolismo , Mucosa Bucal/enzimologia , Palato/enzimologia , Extração Dentária , Animais , Ratos , Fatores de Tempo , CicatrizaçãoRESUMO
Recently CHK2 was functionally linked to the p53 pathway, and mutations in these two genes seem to result in a similar Li-Fraumeni syndrome (LFS) or Li-Fraumeni-like syndrome (LFL) multi-cancer phenotype frequently including breast cancer. As CHK2 has been found to bind and regulate BRCA1, the product of one of the 2 known major susceptibility genes to hereditary breast cancer, it also more directly makes CHK2 a suitable candidate gene for hereditary predisposition to breast cancer. Here we have screened 79 Finnish hereditary breast cancer families for germline CHK2 alterations. Twenty-one of these families also fulfilled the criteria for LFL or LFS. All families had previously been found negative for germline BRCA1, BRCA2 and TP53 mutations, together explaining about 23% of hereditary predisposition to breast cancer in our country. Only one missense-type mutation, Ile(157)-->Thr(157), was detected. The high Ile(157)--> Thr(157)mutation frequency (6.5%) observed in healthy controls and the lack of other mutations suggest that CHK2 does not contribute significantly to the hereditary breast cancer or LFL-associated breast cancer risk, at least not in the Finnish population. For Ile(157)--> Thr(157)our result deviates from what has been reported previously.
Assuntos
Neoplasias da Mama/genética , Mutação em Linhagem Germinativa , Proteínas Quinases/genética , Proteínas Serina-Treonina Quinases , Quinase do Ponto de Checagem 2 , Estudos de Coortes , Feminino , Humanos , Masculino , LinhagemRESUMO
Chromosome 11q deletions are common in various malignancies, including ovarian cancer. However, the clinical significance of these genetic lesions as well as their more precise chromosomal location is largely unknown. Here we have examined epithelial ovarian cancer material from 49 patients for loss of heterozygosity (LOH) using nine microsatellite markers on 11q22.3-q25 and evaluated the effect of observed deletions with regard to different clinicopathological variables. LOH was detected in 61% of the patients. Interestingly, LOH for the D11S1340 marker locus at 11q23. 3 seemed to be associated with significantly reduced survival times (P = 0.005) and serous tumor histology (P = 0.036). LOH for D11S912 at the more distal 11q24-q25 location correlated with a higher tumor stage (P = 0.003), serous tumor histology (P = 0.015), and finding of residual tumor (P = 0.047), but not directly with survival times (P = 0.320). The majority of the analyzed tumors simultaneously displayed deletions at two distinct 11q regions, A and B, which are proximal and distal to D11S1347/NCAM (11q23.2-q23.3), respectively. Only LOH for two markers (D11S1340 and D11S912) of the B region seemed to be directly associated with a more aggressive disease course. Therefore, it appears that deletions of the ataxia telangectasia gene of the A region would not be crucial for determining the outcome of ovarian cancer. Our present results indicate that a survival factor gene in ovarian cancer would be located close to D11S1340 at 11q23.3. This corresponds well to our earlier observation in breast cancer, suggesting the involvement of a shared survival factor gene in both diseases.
Assuntos
Cromossomos Humanos Par 11 , Perda de Heterozigosidade , Neoplasias Ovarianas/genética , Feminino , Marcadores Genéticos , Humanos , Neoplasias Ovarianas/patologiaRESUMO
We have screened for germline TP53 mutations in Finnish BRCA1 and BRCA2 mutation-negative families. This study represents the largest survey of the entire protein-encoding portion of TP53, and indicates that mutations are only found at conserved domains in breast cancer families also meeting the criteria for Li-Fraumeni/Li-Fraumeni-like syndrome, explaining only a very small additional fraction of the hereditary breast cancer cases.
Assuntos
Neoplasias da Mama/genética , Sequência Conservada/genética , Genes p53/genética , Mutação em Linhagem Germinativa/genética , Síndromes Neoplásicas Hereditárias/genética , Proteína Supressora de Tumor p53/genética , Estudos de Coortes , Feminino , Finlândia/etnologia , Humanos , LinhagemRESUMO
High frequencies of loss of heterozygosity (LOH) in chromosome 11q22-qter have been observed in various malignancies, including breast cancer. Previous studies on breast carcinomas by Winqvist et al (Cancer Res 55: 2660-2664) have indicated that a survival factor gene is located in band 11q23, and that the highly informative microsatellite polymorphism at the APOC3 locus would be a suitable tool to perform more extensive LOH studies. In this European multicentre study, we have examined the occurrence of APOC3 LOH and evaluated the effect of LOH of this chromosomal subregion on the clinical behaviour of the disease in a cohort of 766 breast cancer patients in more detail. LOH for APOC3 was found in 42% of the studied tumours, but it was not found to be significantly associated with any of the studied clinical variables, including cancer-specific survival time or survival time after recurrent/metastatic disease. According to the present findings, the putative survival factor gene on 11q23 is not located close enough to the APOC3 gene, but apparently at a more proximal location.
Assuntos
Apolipoproteínas C/genética , Neoplasias da Mama/genética , Cromossomos Humanos Par 11 , Perda de Heterozigosidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Europa (Continente) , Feminino , Marcadores Genéticos , Humanos , Pessoa de Meia-IdadeRESUMO
Among the chromosomal regions commonly undergoing deletions in breast tumors is 11q23.1. The genes that are targets for loss of heterozygosity (LOH) in this region is not yet established. One of the candidate genes located in this region is ATM, responsible for the rare autosomal recessive disorder ataxia-telangiectasia (A-T). Interestingly, A-T heterozygotes may have an increased risk of cancer, in particular breast cancer, although this is still controversial. A common assumption has been that the target for the LOH at 11q23.1 in breast carcinoma is the ATM gene, but the area studied has been too large, the density of markers too low, and the number of tumors studied has been too small to draw any firm conclusions. The present study is a multicenter study including 918 breast cancer patients with clinical information and survival data available for most of them. Primary breast tumors were investigated for LOH using a high density of microsatellite markers spanning approximately 6 Mb around the ATM gene. Survival analyses showed that there are most likely one or more candidate genes in a 3-4 Mb region between the markers D11S1819 and D11S927 including the ATM gene. Cancer-specific survival was significantly reduced in patients whose tumors exhibited LOH of markers D11S2179 (within the ATM gene), D11S1778, D11S1294, and D11S1818. The highest survival hazard ratios were 1.8(C11.2-2.8, P = 0.010) and 2.1 (C11.4-3.0, P = 0.0004) for markers D11S2179 and D11S1818, respectively. One or more of these markers are therefore most likely to be located close to or within genes associated with breast cancer survival.